Calgary, Alberta--(Newsfile Corp. - August 12, 2026) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") is pleased to announce the appointment of Prof. Dr. Ernst von Schwarz, MD, PhD, FESC, FACC, FSCAI, as Principal Investigator of Hemostemix' VesCell (ACP-01) longevity clinical trial. About Prof. Dr. Ernst von SchwarzDr. von Schwarz brings more than three decades of cardiovascular, academic and regenerative-medicine experience to the study. "There is an important connection between cardiovascular health and longevity: our organs cannot remain healthy without adequate circulation," said Dr. von Schwarz. In Hemostemix' clinical trials, findings less than p<0.05 provide increasingly strong evidence that the improvements were not due to chance. "Combined with his work on HeartCode, Dr. von Schwarz is recognized as an expert who details how to extend healthy, fully functional life well past age 100!